Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro

Haematologica

Volumn 87, Issue 2, 2002, Pages 167-176

  Ganeshaguru, Kanagasabai ^a   Wickremasinghe, Ranmohan G ^a   Jones, Dylan T ^a   Gordon, Mathew ^a   Hart, Steve M ^a   Virchis, Andres E ^a   Prentice, H Grant ^a   Hoffbrand, A Victor ^a   Man, Anthony ^a   Champain, Kate ^a   Csermak, Katalin ^a   Mehta, Atul B ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Apoptosis; B chronic lymphocytic leukemia; Multidrug resistance; PKC412; Protein kinase C

Indexed keywords

2' CHLORODEOXYADENOSINE; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CELL DNA; CHLORAMBUCIL; CYTOTOXIC AGENT; DAUNORUBICIN; FLUDARABINE; GLYCOPROTEIN P; ISOENZYME; MIDOSTAURIN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; STAUROSPORINE DERIVATIVE; UNCLASSIFIED DRUG; VERAPAMIL;

ADULT; AGED; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; CELL STRUCTURE; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TRANSPORT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LEUKEMIA CELL; MALE; NICK END LABELING; PERIPHERAL LYMPHOCYTE; PHASE 2 CLINICAL TRIAL; PROTEIN EXPRESSION; TONSIL CELL; TREATMENT OUTCOME;

2-CHLOROADENOSINE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; B-LYMPHOCYTES; CALCIUM CHANNEL BLOCKERS; CHLORAMBUCIL; DEOXYADENOSINES; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; FEMALE; HUMANS; IN SITU NICK-END LABELING; LEUKEMIA, B-CELL, CHRONIC; MALE; MIDDLE AGED; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROTEIN KINASE C; STAUROSPORINE; TONSIL; TUMOR CELLS, CULTURED; VERAPAMIL; VIDARABINE;

EID: 0036175273     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. The potential of protein kinase C as a target for anticancer treatment
2. The extended protein kinase C super-family
3. The ε form of protein kinase C is an oncogene when overexpressed in rat fibroblasts
4. Human interleukin-3 receptor modulates bcl-2 mRNA and protein levels through protein kinase C in TF-1 cells
5. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of BCL-2 α in association with suppression of apoptosis
6. + antiporter
7. An essential role for NF-κ B in preventing TNF-α-induced cell death
8. Suppression of TNF α induced apoptosis by NF-κ B
9. TNF- and cancer therapy-induced apoptosis: Potentiation by inhibition of NF-κ B
10. Modulation of drug induced apoptosis by interruption of the protein kinase C signal transduction pathway: A new therapeutic strategy
11. Protein kinase C: A worthwhile target for anticancer drugs?
12. Effects of phosphorylation of P-gp on multidrug resistance
13. Modulation of P-glycoprotein by protein kinase C α in a baculovirus expression system
14. Interaction of P-glycoprotein with protein kinase C in human multidrug resistant carcinoma cells
15. Decreased protein kinase C activity is associated with programmed cell death (apoptosis) in freshly isolated rat hepatocytes
16. Induction of a common pathway of apoptosis by staurosporine
17. Protein kinase C and mammary cell differentiation: Involvement of protein kinase C α in the induction of β-casein expression
18. Effects of a new protein kinase C inhibitor CGP 41251 on T-cell functions: Inhibition of activation, growth and target cell killing
19. Comparison of staurosporine and four analogues: Their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells
20. Effects of protein kinase C inhibitor, staurosporine derivative CGP 41 251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines
21. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C
22. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with anti tumour activity, reverses multidrug resistance
23. The antitumour activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251
24. Multidrug resistance in chronic lymphocytic leukaemia
25. MDR1 and MRP expression in chronic B-cell lymphoproliferative disorders
26. α-interferon (α-IFN) protects B-chronic lymphocytic leukaemia cells from apoptotic cell death in vitro
27. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro
28. Flow cytometric assessment of multidrug resistance (MDR) phenotype in acute myeloid leukaemia (AML)
29. Correlation of multidrug resistance (MDR-1) protein expression with functional dye/drug efflux in acute myeloid leukaemia by multiparameter flow cytometry: Identification of discordant MDR-efflux+ and MDR+efflux- cases
30. A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro antiproliferative as well as in vivo anti-tumor activity
31. Chronic lymphocytic leukemia: New insights into biology and therapy
32. Autologous plasma activates akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells
33. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation
34. Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukaemia
35. A role for P-glycoprotein in regulating cell death
36. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients
37. Expression of PKC isoenzyme and MDR-associated genes in primary and relapsed state AML
38. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
39. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms
40. Old and new therapies in chronic lymphocytic leukaemia: Now is the time for a reassessment of therapeutic goals
41. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner
42. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C treated gastric cancer cells
43. A pilot clinical/pharmacological study of the protein kinase C specific inhibitor Safingol alone and in combination with doxorubicin
44. Evidence for involvement of mitogen-activated protein kinase, rather than stress-activated protein kinase, in potentiation of 1-β-D-arabinofuranosylcytosine-induced apoptosis by interruption of protein kinase C signalling
45. Differential p53-dependent mechanism of radiosensitization in vitro and in vivo by protein kinase C-specific inhibitor PKC412
46. Clinical treatment with CGP41251 increases sensitivity of CLL cells to conventional therapy
47. Protein kinase C targeting in anti-neoplastic treatment strategies